Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,789 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma.
Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, Parkash V, Ning J, Sohani AR, Ferry JA, Mehta-Shah N, Dogan A, Liu H, Thormann N, Di Napoli A, Lade S, Piccolini J, Reyes R, Williams T, McCarthy CM, Hanson SE, Nastoupil LJ, Gaur R, Oki Y, Young KH, Miranda RN. Clemens MW, et al. Among authors: ning j. J Clin Oncol. 2016 Jan 10;34(2):160-8. doi: 10.1200/JCO.2015.63.3412. Epub 2015 Nov 30. J Clin Oncol. 2016. PMID: 26628470 Free PMC article.
Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases.
Nagarajan P, Curry JL, Ning J, Piao J, Torres-Cabala CA, Aung PP, Ivan D, Ross MI, Levenback CF, Frumovitz M, Gershenwald JE, Davies MA, Malpica A, Prieto VG, Tetzlaff MT. Nagarajan P, et al. Among authors: ning j. Clin Cancer Res. 2017 Apr 15;23(8):2093-2104. doi: 10.1158/1078-0432.CCR-16-2126. Epub 2016 Nov 18. Clin Cancer Res. 2017. PMID: 27864417
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma.
Tetzlaff MT, Adhikari C, Lo S, Rawson RV, Amaria RN, Menzies AM, Wilmott JS, Ferguson PM, Ross MI, Spillane AJ, Vu KA, Ma J, Ning J, Haydu LE, Saw RPM, Wargo JA, Tawbi HA, Gershenwald JE, Long GV, Davies MA, Scolyer RA. Tetzlaff MT, et al. Among authors: ning j. Ann Oncol. 2020 Nov;31(11):1569-1579. doi: 10.1016/j.annonc.2020.07.016. Epub 2020 Jul 31. Ann Oncol. 2020. PMID: 32739408 Free article.
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.
Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Short NJ, et al. Among authors: ning j. Blood Adv. 2020 Nov 24;4(22):5681-5689. doi: 10.1182/bloodadvances.2020003120. Blood Adv. 2020. PMID: 33211826 Free PMC article.
Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.
Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Takahashi K, et al. Among authors: ning j. Blood. 2013 Oct 17;122(16):2807-11; quiz 2920. doi: 10.1182/blood-2013-03-491399. Epub 2013 Jul 29. Blood. 2013. PMID: 23896412 Free PMC article.
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. Short NJ, et al. Among authors: ning j. Am J Hematol. 2019 Jan;94(1):74-79. doi: 10.1002/ajh.25318. Epub 2018 Nov 15. Am J Hematol. 2019. PMID: 30328139 Free PMC article. Clinical Trial.
Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.
Blessing AM, Santiago-O'Farrill JM, Mao W, Pang L, Ning J, Pak D, Bollu LR, Rask P, Iles L, Yang H, Tran S, Elmir E, Bartholomeusz G, Langley R, Lu Z, Bast RC Jr. Blessing AM, et al. Among authors: ning j. Cancer. 2020 Aug 1;126(15):3579-3592. doi: 10.1002/cncr.32985. Epub 2020 Jun 2. Cancer. 2020. PMID: 32484926 Free PMC article.
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality.
Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Issa GC, et al. Among authors: ning j. Leukemia. 2020 Nov;34(11):2914-2924. doi: 10.1038/s41375-020-0916-8. Epub 2020 Jun 16. Leukemia. 2020. PMID: 32546726 Clinical Trial.
1,789 results